Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorABOU-HAMDAN, M
dc.contributor.authorSALEH, R
dc.contributor.authorMANI, S
dc.contributor.authorDOURNAUD, P
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorMETIFIOT, Mathieu
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorBLONDOT, Marie-Lise
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorANDREOLA, Marie-Aline
dc.contributor.authorABDEL SATER, F
dc.contributor.authorDE REGGI, Max
dc.contributor.authorGRESSENS, P
dc.contributor.authorLAFORGE, M
dc.date.accessioned2023-05-17T08:07:57Z
dc.date.available2023-05-17T08:07:57Z
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/182185
dc.description.abstractEnAbstract SARS-CoV-2 interacts with cellular cholesterol during many stages of its replication cycle. Pantethine was reported to reduce total cholesterol levels and fatty acid synthesis and potentially alter different processes that might be involved in the SARS-CoV-2 replication cycle. Here, we explored the potential antiviral effects of pantethine in two in vitro experimental models of SARS-CoV-2 infection.Pantethine reduced the infection of cells by SARS-CoV-2 in both preinfection and postinfection treatment regimens. Accordingly, cellular expression of the viral spike and nucleocapsid proteins was substantially reduced, and we observed a significant reduction in viral copy numbers in the supernatant of cells treated with pantethine. In addition, pantethine inhibited the infection-induced increase in TMPRSS2 and HECT E3 ligase expression in infected cells as well as the increase in antiviral interferon-beta response and inflammatory gene expression in Calu-3a cells. Our results demonstrate that pantethine, which is well tolerated in humans, was very effective in controlling SARS-CoV-2 infection and might represent a new therapeutic drug that can be repurposed for the prevention or treatment of COVID-19 and long COVID syndrome.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enPantethine
dc.subject.enantiviral
dc.subject.enSARS-CoV-2
dc.subject.enCOVID-19
dc.subject.enE3 ligases
dc.subject.enin ammation
dc.title.enPotential antiviral effects of pantethine against SARS-CoV-2
dc.typeDocument de travail - Pré-publicationen_US
dc.identifier.doi10.21203/rs.3.rs-1630994/v1en_US
dc.subject.halSciences du Vivant [q-bio]/Microbiologie et Parasitologie/Virologieen_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.institutionCNRSen_US
bordeaux.import.sourcehal
hal.identifierhal-03819533
hal.version1
hal.exportfalse
workflow.import.sourcehal
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.au=ABOU-HAMDAN,%20M&SALEH,%20R&MANI,%20S&DOURNAUD,%20P&METIFIOT,%20Mathieu&rft.genre=preprint


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée